Astellas withdraws lawsuit after evading Medicare drug price negotiations

WASHINGTON — Astellas was so sure that one of its drugs was going to be selected as part of Medicare’s new drug price negotiation program that the company preemptively sued the Biden administration.

But it turns out that its blockbuster drug Xtandi didn’t get picked for the program, after all. So on Wednesday, the company withdrew its lawsuit.

Astellas said in a statement that the company’s choice to withdraw its lawsuit does not change its belief that the drug price negotiation program created in the Inflation Reduction act is “bad policy and unconstitutional.”

Get unlimited access to award-winning journalism and exclusive events.

CG Oncology aims for $181M listing in first biotech IPO of 2024

CG Oncology appears poised to be the first biotech IPO of 2024 as it disclosed Thursday morning it will seek about $181 million in its

January 19, 2024

What are the needs for clinical application of next-generation sequencing for microbiological diagnosis?

Scientists have surveyed to understand the need for clinical application of next-generation sequencing in microbiology laboratories.

August 23, 2023

The U.S. must raise federal alcohol taxes to address the alarming rise in alcohol use

Eleven years ago, two days before Christmas, my 24-year-old brother, who was a university graduate and former law student, died from a self-inflicted gunshot wound.

December 20, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.